AVONEX Q & A
AVONEX
Tysabri (natalizumab) – study how Tysabri effects quality of life in multiple sclerosis
Tysabri (natalizumab) – study how Tysabri effects quality of life in multiple sclerosis
Department of Neurology,
Mellen Center for Multiple Sclerosis Treatment and Research,
Cleveland Clinic Foundation,
Cleveland, OH.
OBJECTIVE:
Stem Cell Therapies- International Distribution System
Vavici™ Announces Formation of First Comprehensive International Distribution System for Stem Cell Therapies
NEW YORK–(BUSINESS WIRE)—
Tysabri – when stopping using there is increase disease activity
Disease Activity Increases After MS Patients Stop Natalizumab (Tysabri) Treatment
ATL1102 Phase IIa Multiple Sclerosis Trial Update
ATL1102 Phase IIa Multiple Sclerosis Trial Update
Antisense Therapeutics Limited is pleased to provide the following update on its ATL1102 Phase IIa Multiple Sclerosis (MS) clinical trial
VICTORIA, Australia | September 12, 2007 | Antisense Therapeutics Limited (ASX:ANP) is pleased to provide the following update on its ATL1102 Phase IIa Multiple Sclerosis (MS) clinical trial.
The Company is currently conducting this 80 patient trial… read more »
Disease Benefit with HE3286 in Model of Multiple Sclerosis
Disease Benefit with HE3286 in Model of Multiple Sclerosis Highlighted at 2nd International Congress on Immune-Mediated Diseases…
VITAMIN D SUPPLEMENTS
VITAMIN D SUPPLEMENTS APPEAR TO BE ASSOCIATED WITH LOWER RISK OF DEATH
COPAXONE® Had Significantly Lower Risk of Relapse than Patients Using Rebif®
Study Showed Patients Using COPAXONE® Had Significantly Lower Risk of Relapse and Lower Medical Costs Compared to Patients Using Rebif® in Relapsing-Remitting Multiple Sclerosis (RRMS)
Acne Medication May Delay Progress of Multiple Sclerosis
Multiple Sclerosis Society of Canada Oct 25, 2007 12:30 ET
